Acrivon Files New $300M Shelf Days After Disclosing Going-Concern Doubt
ACRV is trading near its 52-week low of $1.27 (13% above the low).
Summary
Acrivon filed a new $300 million shelf registration, mostly rolled forward from its 2023 shelf, giving it the paperwork to raise cash while it warns of going-concern doubt. No shares have been sold and no terms are set.
Key Events · Financing and Capital Events · ACRV
-
New $300M Universal Shelf Filed
Registers up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units for sale from time to time; no securities have been sold and no pricing is set.
-
Most Capacity Is Rolled Forward
Of the total, $292,701,082.80 is unsold capacity carried forward from the prior S-3 (File No. 333-275854, effective December 15, 2023) under Rule 415(a)(6); only $7,298,917.20 is newly registered, with a $635.01 fee.
-
Float Cap Limits Near-Term Raises
Non-affiliate float was about $34.6 million as of November 10, 2026, so General Instruction I.B.6 caps sales at one-third of float — roughly $11.5 million — in any 12-month period while float stays under $75 million.
-
Filed Alongside Going-Concern Warning
The shelf arrives the same day as the Q3 2026 10-Q, which reported a $17.9 million net loss, $77.8 million in cash, and substantial doubt about continuing as a going concern.
Analysis · ACRV · Life Sciences
The timing is what matters here: this shelf lands the same day the company's 10-Q disclosed substantial doubt about its ability to continue as a going concern, with $77.8 million in cash against a $17.9 million quarterly net loss. Acrivon registered a fresh $300 million universal shelf, but only $7.3 million of that is new capacity — the other $292.7 million is unsold capacity rolled forward from its 2023 shelf, which terminates when this one goes effective. No shares have been sold and no terms are set; any actual raise requires a separate prospectus supplement. And because the non-affiliate float is only about $34.6 million, the one-third-of-float rule caps what Acrivon can actually sell in any 12-month window at roughly $11.5 million until the float recovers — so the headline number overstates near-term firepower. Expect the real dilution news in a future 424B supplement, not here.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.6M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.